Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

331 ARTÍCULOS , VIENDO DEL 46 AL 60

Therapeutic approaches to modulating glutathione levels as a pharmacological strategy in Alzheimer's disease

Peter C, Braidy N, Zarka M, Welch J, Bridge W.

Curr Alzheimer Res. 2015;12(4):298-313. doi: 10.2174/1567205012666150302160308.

Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies

Arai H, Suzuki H, Yoshiyama T.

Curr Alzheimer Res. 2015;12(3):242-54. doi: 10.2174/1567205012666150302154121.

Effect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimer's disease (review)

Jiang J, Jiang H.

Mol Med Rep. 2015 Jul;12(1):3-12. doi: 10.3892/mmr.2015.3424. Epub 2015 Mar 4.

Growth factor treatment to overcome Alzheimer's dysfunctional signaling

Lauzon MA, Daviau A, Marcos B, Faucheux N.

Cell Signal. 2015 Jun;27(6):1025-38. doi: 10.1016/j.cellsig.2015.02.018. Epub 2015 Mar 3.

Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review

West S, Bhugra P.

Br J Clin Pharmacol. 2015 Aug;80(2):221-34. doi: 10.1111/bcp.12621. Epub 2015 Jun 8.

Stem cell therapy for Alzheimer's disease and related disorders: current status and future perspectives

Tong LM, Fong H, Huang Y.

Exp Mol Med. 2015 Mar 13;47(3):e151. doi: 10.1038/emm.2014.124.

β-sheet interfering molecules acting against β-amyloid aggregation and fibrillogenesis

Francioso A, Punzi P, Boffi A, Lori C, Martire S, Giordano C, D'Erme M, Mosca L.

Bioorg Med Chem. 2015 Apr 15;23(8):1671-83. doi: 10.1016/j.bmc.2015.02.041. Epub 2015 Feb 28.

First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study

Andreasen N, Simeoni M, Ostlund H, Lisjo PI, Fladby T, Loercher AE, Byrne GJ, Murray F, Scott-Stevens PT, Wallin A, Zhang YY, Bronge LH, Zetterberg H, Nordberg AK, Yeo AJ, Khan SA, Hilpert J, Mistry PC.

PLoS One. 2015 Mar 19;10(3):e0098153. doi: 10.1371/journal.pone.0098153. eCollection 2015.

Immunotherapeutic approaches for Alzheimer's disease

Wisniewski T, Goñi F.

Neuron. 2015 Mar 18;85(6):1162-76. doi: 10.1016/j.neuron.2014.12.064.

Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment

Li X, Song D, Leng SX.

Clin Interv Aging. 2015 Mar 10;10:549-60. doi: 10.2147/CIA.S74042. eCollection 2015.

Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer's disease

Lauzon MA, Daviau A, Marcos B, Faucheux N.

J Control Release. 2015 May 28;206:187-205. doi: 10.1016/j.jconrel.2015.03.024. Epub 2015 Mar 22.

EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease

Schmidt R, Hofer E, Bouwman FH, Buerger K, Cordonnier C, Fladby T, Galimberti D, Georges J, Heneka MT, Hort J, Laczó J, Molinuevo JL, O'Brien JT, Religa D, Scheltens P, Schott JM, Sorbi S.

Eur J Neurol. 2015 Jun;22(6):889-98. doi: 10.1111/ene.12707. Epub 2015 Mar 25.

Nonpharmacological therapy for the management of neuropsychiatric symptoms of Alzheimer's disease: linking evidence to practice

Staedtler AV, Nunez D.

Worldviews Evid Based Nurs. 2015 Apr;12(2):108-15. doi: 10.1111/wvn.12086. Epub 2015 Mar 21.

Oxidant/Antioxidant imbalance and the risk of Alzheimer's disease

Moneim AE.

Curr Alzheimer Res. 2015;12(4):335-49. doi: 10.2174/1567205012666150325182702.

Regulation of extracellular Zn(2+) homeostasis in the hippocampus as a therapeutic target for Alzheimer's disease

Takeda A, Tamano H.

Expert Opin Ther Targets. 2015;19(8):1051-8. doi: 10.1517/14728222.2015.1029454. Epub 2015 Mar 27.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias